TDM in Psychiatry. First Update of the AGNP Consensus Guidelines
作者
Christoph Hiemke
出处
期刊:Pharmacopsychiatry [Thieme Medical Publishers (Germany)] 日期:2008-09-01卷期号:41 (05)
标识
DOI:10.1055/s-0028-1088254
摘要
Therapeutic Drug Monitoring (TDM) uses drug concentrations to manage the medication regimen of an individual patient and optimize outcome. Since the practical use of TDM in psychiatry is far from optimal, the TDM group of the Arbeitsgemeinschaft fuer Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) has worked out guidelines in 2004 [1]. Literature based optimal plasma concentrations were established for 65 psychoactive drugs. The best practice of TDM in psychiatry was described in detail, i.e. the decision to request a drug level, the taking of a blood sample, the measuring of plasma or serum concentrations in the laboratory, the clinical interpretation of the results and the final therapeutic management. Meanwhile new psychoactive drugs have been introduced on the market, new analytical techniques are available in the laboratories and new data on drug concentrations and clinical outcome have been reported. Optimal target ranges had to be defined by the TDM group of the AGNP for the new drugs, and for some old psychoactive drugs reported target ranges had to be revised. Therefore it was necessary to update the consensus guidelines for drugs in psychiatry. In addition to the target ranges considered as optimal for response dose related concentrations were defined. This is of special importance to identify non-compliance or patients with abnormal drug metabolism. The consensus update gives more detailed instructions how to use TDM in psychiatry when treating children or adolescents, aged patients, patients during and after pregnancy or addictive patients. The TDM group has also defined the use of pharmacogenetic tests to improve the response to psychopharmacotherapy. The consensus update shall further improve the use of TDM in psychiatry. When TDM is used adequately, it is helpful for many psychiatric patients and in many situations. Literature: [1] Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, Kuss HJ, Laux G, Mueller-Oerlinghausen B, Rao ML, Riederer P, Zernig G. AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiat 2004; 37: 243–65.